Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:DRUG NASDAQ:NBTX NYSE:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.82-2.6%$0.82$0.55▼$1.66$108.48M1.1454,040 shs592,476 shsDRUGBright Minds Biosciences$48.66-0.2%$36.88$0.94▼$79.02$343.39M-6.1370,255 shs34,378 shsNBTXNanobiotix$9.32-3.9%$7.52$2.76▼$10.59$464.99M0.4714,564 shs5,122 shsOSTXOS Therapies$2.20-2.2%$1.97$1.12▼$7.00$69.62MN/A720,484 shs324,156 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.57%+1.38%+5.37%+0.95%-46.17%DRUGBright Minds Biosciences-0.18%+13.24%+16.36%+75.73%+3,716.47%NBTXNanobiotix-3.92%+7.00%+17.83%+102.39%+88.28%OSTXOS Therapies-2.22%-1.79%+6.80%+22.91%-36.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.82-2.6%$0.82$0.55▼$1.66$108.48M1.1454,040 shs592,476 shsDRUGBright Minds Biosciences$48.66-0.2%$36.88$0.94▼$79.02$343.39M-6.1370,255 shs34,378 shsNBTXNanobiotix$9.32-3.9%$7.52$2.76▼$10.59$464.99M0.4714,564 shs5,122 shsOSTXOS Therapies$2.20-2.2%$1.97$1.12▼$7.00$69.62MN/A720,484 shs324,156 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.57%+1.38%+5.37%+0.95%-46.17%DRUGBright Minds Biosciences-0.18%+13.24%+16.36%+75.73%+3,716.47%NBTXNanobiotix-3.92%+7.00%+17.83%+102.39%+88.28%OSTXOS Therapies-2.22%-1.79%+6.80%+22.91%-36.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17653.69% UpsideDRUGBright Minds Biosciences 3.11Buy$81.0066.46% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00-14.16% DownsideOSTXOS Therapies 3.00Buy$18.00718.18% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, NBTX, ATOS, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.009/12/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/8/2025DRUGBright Minds BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/2/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/27/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/20/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.008/7/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/14/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/ANBTXNanobiotix$39.18M11.40N/AN/A($1.51) per share-6.17OSTXOS TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.23N/AN/AN/AN/A-40.28%-37.10%11/11/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/ANBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)OSTXOS Therapies-$7.79M-$0.79N/AN/AN/AN/AN/A-569.57%N/ALatest OSTX, NBTX, ATOS, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/12/2025Q2 2025ATOSAtossa Genetics-$0.06-$0.07-$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A9.179.17DRUGBright Minds BiosciencesN/A86.6486.64NBTXNanobiotixN/A1.041.04OSTXOS TherapiesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%DRUGBright Minds Biosciences40.52%NBTXNanobiotix38.81%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipATOSAtossa Genetics8.70%DRUGBright Minds Biosciences42.66%NBTXNanobiotix3.45%OSTXOS Therapies10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million117.93 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionableOSTXOS TherapiesN/A31.65 millionN/AN/AOSTX, NBTX, ATOS, and DRUG HeadlinesRecent News About These CompaniesOS Therapies (NYSE:OSTX) Receives "Buy" Rating from D. Boral CapitalSeptember 14 at 11:34 AM | marketbeat.comOS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last VisitSeptember 12, 2025 | newsfilecorp.comNStonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)September 8, 2025 | newsfilecorp.comND. Boral Capital Reaffirms "Buy" Rating for OS Therapies (NYSE:OSTX)September 4, 2025 | marketbeat.comOS Therapies to Participate in Upcoming Investor Conferences in September 2025September 3, 2025 | newsfilecorp.comNOS Therapies Raises $3.7M for OST-HER2 LaunchSeptember 2, 2025 | tipranks.comOS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 MeetingSeptember 2, 2025 | newsfilecorp.comNOS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 FinancingSeptember 2, 2025 | newsfilecorp.comND. Boral Capital Reiterates "Buy" Rating for OS Therapies (NYSE:OSTX)August 29, 2025 | marketbeat.comOS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025August 27, 2025 | newsfilecorp.comNOS Therapies Ends Equity Agreement with Square GateAugust 26, 2025 | tipranks.comOS Therapies Reports Progress in Osteosarcoma TreatmentAugust 25, 2025 | tipranks.comOS Therapies Terminates Equity Line of CreditAugust 25, 2025 | newsfilecorp.comNOS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral CapitalAugust 22, 2025 | marketbeat.comOS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details UnavailableAugust 19, 2025 | gurufocus.comOS Therapies Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 19, 2025 | newsfilecorp.comNEarnings Outlook For OS TherapiesAugust 18, 2025 | benzinga.comOS Therapies Updates Quorum Rules for Shareholder MeetingsAugust 15, 2025 | tipranks.comOS Therapies Delays Q2 2025 Financial ReportAugust 15, 2025 | tipranks.comOS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025August 14, 2025 | newsfilecorp.comNOS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...August 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Next-Gen Defense: 3 Stocks Riding the New Global Arms RaceBy Nathan Reiff | August 18, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025OSTX, NBTX, ATOS, and DRUG Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.82 -0.02 (-2.57%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.10%) As of 09/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Bright Minds Biosciences NASDAQ:DRUG$48.66 -0.09 (-0.18%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$48.36 -0.31 (-0.63%) As of 09/15/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Nanobiotix NASDAQ:NBTX$9.46 -0.24 (-2.42%) As of 09/15/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.OS Therapies NYSE:OSTX$2.20 -0.05 (-2.22%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$2.24 +0.04 (+1.82%) As of 09/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
